Doris Hansen, MD

Cancer Focus:
Multiple Myeloma-Plasma Cell Disorders

Clinical Trial 23203
A Phase 1, Open-Label, Dose-Finding Study of BMS-986453, Dual Targeting BCMAxGPRCSD Chimeric Antigen Receptor T Cells, in Participants with Relapsed and/or Refractory Multiple Myeloma
Condition: Malignant Hematology
Intervention: BMS-986453 (); cyclophosphamide (); cytoxan (cyclophosphamide); fludarabine (Fludarabine phosphate)
Status: Open

Clinical Trial 23586
A Phase 1b/2 Study of AZD0120, a Dual-Targeting Autologous Chimeric Antigen Receptor T-cell (CAR T) Therapy Directed Against CD19 and B-cell Maturation Antigen (BCMA) in Participants with Relapsed/Refractory Multiple Myeloma
Condition: Multiple Myeloma
Intervention: AZD0120 (); GC012F (); cyclophosphamide (); cytoxan (cyclophosphamide); fludarabine (Fludarabine phosphate)
Status: Open

If you believe you are eligible for one of these trials or studies, please call
813-745-6100 or toll-free 1-800-679-0775.

• Banerjee R, Kaur G, Razzo BM, Portuguese AJ, Sidana S, Richards T, Grajales-Cruz A, Richard S, Shune L, Khouri J, Dima D, Lee HC, Patel KK, Pasvolsky O, Vazquez-Martinez M, Hansen DK, Afrough A, Davis JA, Hashmi H, Atrash S, Ferreri CJ, Julian KL, Herr MM, Midha S, Costello P, Forsberg P, de Menezes Silva Corraes A, Lin Y, Cowan AJ, Anderson LD, Garfall AL. Predictors of Delayed Responses to Teclistamab in Multiple Myeloma After Initial Non-Response. Am J Hematol. 2026 Jan.101(1):169-173. Pubmedid: 41074685.
• Dhakal B, Akhtar OS, Fandrei D, Jensen A, Banerjee R, Pan D, Richard S, Friend R, Rees MJ, Costello P, Vazquez Martinez MA, Pasvolsky O, Wagner CB, Davis JA, Castaneda Puglianini OA, Reshef R, Afrough A, Dima D, Bhutani M, Nadeem O, Parrondo RD, Freeman CL, Mikkilineni L, Raza S, Anderson LD, Kapoor P, Hosoya H, Chhabra S, Grajales-Cruz A, Gaballa MR, Midha S, Alsina M, Sborov DW, Patel KK, Lin Y, Ferreri CJ, Gagelmann N, Kumar AD, Hansen DK, Cowan AJ, Costa LJ, Merz M, Sidana S. Sequential targeting in multiple myeloma: talquetamab, a GPRC5D bispecific antibody, as a bridge to BCMA CAR-T therapy. Blood. 2025 Oct.146(17):2063-2072. Pubmedid: 40749169.
• Abuhelwa Z, Amisha F, Fan W, De Avila G, Hansen DK, Grajales-Cruz AF, Blue B, Castaneda O, Liu H, Freeman CL, Nishihori T, Locke FL, Shain KH, Baz R, Alsina M. Post-progression outcomes following BCMA-directed CAR T-cell therapy in myeloma: impact of extramedullary and paramedullary disease. Front Oncol. 2025 Oct.15:1663814. Pubmedid: 41220935. Pmcid: PMC12597725.
• Gaskill E, Albanyan O, Naqvi SMH, Mo Q, Belfon A, Nishihori T, Faramand R, Lazaryan A, Hansen DK, Khimani F, Mishra A, Nieder M, Perez L, Liu H, Pidala J, Anasetti C, Bejanyan N, Elmariah H. Impact of Obesity and Weight-Based Chemotherapy Dosing Adjustments on Outcomes of Allogeneic Hematopoietic Cell Transplant for Acute Myeloid Leukemia. Transplant Cell Ther. 2025 Oct. Pubmedid: 41115629.
• Razzo BM, Midha S, Portuguese AJ, Grajales-Cruz AF, De Menezes Silva Corraes A, Costello P, Liu Y, Sperling AS, Nadeem O, Dima D, Banerjee R, Cowan AJ, Afrough A, Anderson LD, Lieberman-Cribbin A, Kaur G, Goyal A, Atrash S, Ferreri CJ, Voorhees PM, Pasvolsky O, Lee HC, Patel KK, Julian KL, Forsberg PA, Herr MM, Chhabra S, Parrondo RD, Lin Y, Chen A, Susanibar-Adaniya SP, Khouri J, Raza S, Anwer F, Vazquez-Martinez M, Castaneda Puglianini O, Sborov DW, Davis JA, Rossi A, Shune L, Bhurtel J, Hwang WT, Hansen DK, Sidana S, Garfall AL, Richard S. Real-World Experience with Teclistamab for Relapsed/Refractory Multiple Myeloma from the US Myeloma Immunotherapy Consortium. Blood Cancer Discov. 2025 Nov.6(6):561-571. Pubmedid: 40629516.
• Pasvolsky O, Dima D, Feng L, Dong W, Richards T, Davis JA, Afrough A, Vazquez-Martinez M, Sannareddy A, Goel U, Banerjee R, Khouri J, Cervoni F, Gaballa MR, Lieberman-Cribbin A, Rana MS, Julian K, Ferreri CJ, Shune L, DeJarnette S, Bhurtel E, Susanibar Adaniya S, Portuguese A, Hosoya H, Mikkilineni L, Kaur G, Rossi A, Herr MM, Schrum D, Lin C, Raza S, Lin Y, Midha S, Omar N, Atarsh S, McGuirk J, Sborov D, Voorhees P, Anwer F, Alsina M, Freeman C, Garfall AL, Razzo BM, Sidana S, Cowan AJ, Anderson LD, Hansen DK, Richard S, Patel KK, Lee HC, Grajales-Cruz A. Outcomes of elderly patients with relapsed refractory multiple myeloma (RRMM) treated with teclistamab: a multicenter study from the U.S. Multiple Myeloma Immunotherapy Consortium. Blood Cancer J. 2025 May.15(1):92. Pubmedid: 40346049. Pmcid: PMC12064690.
• Hansen DK, Peres LC, Dima D, Richards A, Shune L, Afrough A, Midha S, Dhakal B, Kocoglu MH, Atrash S, Ferreri C, Castaneda O, Davis JA, Bhurtel E, McGuirk J, Wagner C, Bansal R, Costello P, Smith K, Lieberman-Cribbin A, De Avila G, Purvey S, Hosoya H, Mikkilineni L, Oswald LB, Kaur G, Pasvolsky O, Gaballa M, Herr MM, Forsberg P, Janakiram M, Htut M, Asoori Maringanti S, Kalariya N, Hashmi H, Reshef R, Sborov DW, Nadeem O, Anwer F, Khouri J, Raza S, Atanackovic D, Alsina M, Freeman CL, Locke FL, Voorhees P, Anderson LD, Richard S, Martin T, Lin Y, Patel KK, Sidana S. Comparison of Standard-of-Care Idecabtagene Vicleucel and Ciltacabtagene Autoleucel in Relapsed/Refractory Multiple Myeloma. J Clin Oncol. 2025 May.43(13):1597-1609. Pubmedid: 39965175. Pmcid: PMC12037312.
• Banerjee R, Richards A, Midha S, Afrough A, Anwer F, Atanackovic D, Atrash S, Bachanova V, Beitinjaneh AM, Ouchveridze E, Castaneda Puglianini O, Chhabra S, Cicero KI, Davis JA, Dhakal B, Dima D, Ferreri CJ, Forsberg PA, Freeman CL, Herr MM, Jain T, Janakiram M, Khouri J, Kocoglu MH, Kumar AD, Liu Y, Locke FL, McGuirk JP, Mikkilineni L, Nadeem O, Parrondo RD, Pasvolsky O, Peres LC, Purvey S, Raza S, Reshef R, Richard S, Rossi AC, Sborov DW, Shune L, Wagner CB, Zanwar SS, Sidana S, Patel KK, Hansen DK, Kumar SK, Lin Y, Martin TG, Voorhees PM, Anderson LD, Cowan AJ, Kaur G. Universal driving restrictions beyond 4 weeks appear unnecessary following CAR-T therapy in multiple myeloma. Blood Adv. 2025 May.9(9):2336-2340. Pubmedid: 40088469. Pmcid: PMC12127628.
• Afrough A, Abraham PR, Turer L, Kaur G, Sannareddy A, Hansen DK, Anderson LD. Toxicity of CAR T-Cell Therapy for Multiple Myeloma. Acta Haematol. 2025 May.148(3):300-314. Pubmedid: 38718775.
• Gaballa MR, Castaneda Puglianini O, Cohen AD, Vogl DT, Chung A, Ferreri CJ, Voorhees PM, Hansen DK, Patel KK. BCMA-directed CAR T-cell therapy in patients with multiple myeloma and CNS involvement. Blood Adv. 2025 Mar.9(5):1171-1180. Pubmedid: 39729503. Pmcid: PMC11925525.
• Dima D, Vazquez-Martinez MA, Davis JA, Goel U, Afrough A, Sannareddy A, Pasvolsky O, Razzo B, Banerjee R, Khouri J, Grajales-Cruz A, Lieberman-Cribbin A, Rana MS, Julian K, DeJarnette S, Portuguese AJ, Gaballa MR, De Avila G, Susaniba Adaniya S, Raza S, Herr MM, Ouchveridze E, Richards T, Hosoya H, Mikkilineni L, Kaur G, Castaneda Puglianini O, Rossi A, Lin Y, Atrash S, Sborov D, Shain KH, Voorhees PM, Richard S, Garfall AL, Hansen DK, Sidana S, Patel KK, Cowan AJ, Anderson LD, Lee HC, Anwer F, Ferreri CJ, Shune L. Outcomes of teclistamab in patients with relapsed/refractory multiple myeloma with prior exposure to BCMA-directed therapy: a multicenter study from the U.S. Multiple Myeloma Immunotherapy Consortium. Blood Cancer J. 2025 Jun.15(1):111. Pubmedid: 40562770. Pmcid: PMC12198414.
• Banerjee R, Hosoya H, Mikkilineni L, Hansen DK, Wolf JL, Lin Y. Managing IEC-associated enterocolitis following CAR-T therapy in multiple myeloma. Blood Cancer J. 2025 Jun.15(1):112. Pubmedid: 40588476. Pmcid: PMC12209438.
• Dima D, Afrough A, Goel U, Grajales-Cruz A, Khouri J, Julian K, Pasvolsky O, Banerjee R, Razzo B, Ferreri CJ, Vazquez Martinez MA, Davis JA, Sannareddy A, Castaneda Puglianini O, Raza S, Portuguese AJ, Gaballa MR, Rana M, Lieberman-Cribbin A, DeJarnette S, Gonzalez R, Chen A, Herr MM, Mikkilineni L, Hosoya H, Ouchveridze E, Kaur G, Rossi AC, Shune L, Anwer F, Lin Y, Richard S, Sborov DW, Baz RC, Garfall A, Lee HC, Anderson LD, Cowan AJ, Patel KK, Voorhees PM, Sidana S, Susanibar-Adaniya SP, Hansen DK, Atrash S. Teclistamab for patients with heavily pretreated relapsed/refractory multiple myeloma and renal impairment. Blood Adv. 2025 Jul.9(14):3408-3417. Pubmedid: 40198766. Pmcid: PMC12274829.
• Saha S, Rehman L, Rehman A, Darbaniyan F, Weber DM, Becnel M, Gaballa MR, Thomas SK, Lee HC, Chang CC, Arora R, Menges M, Corallo S, Davila ML, Locke FL, Tanner MR, Neelapu SS, Shpall EJ, Flowers CR, Orlowski RZ, Jenq RR, Jain MD, Peterson C, Hansen DK, Saini NY, Patel KK. Longitudinal analysis of gut microbiome and metabolome correlates of response and toxicity with idecabtagene vicleucel. Blood Adv. 2025 Jul.9(14):3429-3440. Pubmedid: 40198765. Pmcid: PMC12274813.
• Sidana S, Ahmed N, Akhtar OS, Brazauskas R, Oloyede T, Bye M, Hansen DK, Ferreri CJ, Freeman CL, Afrough A, Anderson LD, Dhakal B, Dhanda DS, Gowda L, Hashmi H, Harrison MJ, Kitali A, Landau HJ, Mirza AS, Patwardhan P, Qazilbash MH, Usmani SZ, Patel KK, Nishihori T, Ganguly S, Pasquini MC. Standard-of-care idecabtagene vicleucel for relapsed/refractory multiple myeloma. Blood. 2025 Jul.146(2):167-177. Pubmedid: 40198886.
• Dima D, Logue JM, Waqar SHB, Peres LC, Colin-Leitzinger CM, De Avila G, Smith EC, Skelson L, Matte KL, Blue B, Hovanky VN, Gaballa M, Pasvolsky O, Oswald LB, Fortuna GGM, Wagner CB, DeJarnette S, Dillard C, Perna F, Mikkilineni L, Hosoya H, Freeman CL, Shain KH, Baz RC, Grajales-Cruz A, Puglianini OC, Alsina M, Locke FL, Shune LO, Sborov DW, Patel KK, Sidana S, Hansen DK. Cytopenias and infections following ciltacabtagene autoleucel in heavily-pretreated relapsed or refractory multiple myeloma. Haematologica. 2025 Jul. Pubmedid: 40637727.
• Tix T, Alhomoud M, Shouval R, Iacoboni G, Cliff ERS, Hansen DK, Usmani SZ, Salles G, Perales MA, Cordas Dos Santos DM, Rejeski K. Non-relapse mortality with bispecific antibodies: A systematic review and meta-analysis in lymphoma and multiple myeloma. Mol Ther. 2025 Jul.33(7):3163-3176. Pubmedid: 40170355. Pmcid: PMC12266037.
• Sidana S, Patel KK, Peres LC, Bansal R, Kocoglu MH, Shune L, Atrash S, Smith K, Midha S, Ferreri CJ, Dhakal B, Dima D, Costello P, Wagner C, Reshef R, Hosoya H, Mikkilineni L, Atanackovic D, Chhabra S, Parrondo RD, Nadeem O, Mann H, Kalariya N, Hovanky V, DeAvila G, Freeman CL, Locke FL, Alsina M, Wong S, Herr MM, Htut M, McGuirk JP, Sborov DW, Khouri J, Martin T, Janakiram M, Lin Y, Hansen DK. Safety and efficacy of standard-of-care ciltacabtagene autoleucel for relapsed/refractory multiple myeloma. Blood. 2025 Jan.145(1):85-97. Pubmedid: 39365257.
• Hansen DK, Bixby T, Fixler K, Shea L, Martin J, Brittle C, Liu YH, Brunisholz K, Huo JS. Patient and caregiver perspectives on treatment decision-making for stem cell transplantation in multiple myeloma. Support Care Cancer. 2025 Jan.33(2):134. Pubmedid: 39890679.
• Adoncecchi G, Kumar A, Mogili K, Faramand R, Liu H, Khimani F, Mishra A, Nieder M, Nishihori T, Hansen D, Jain M, Lazaryan A, Perez L, Pidala J, Locke F, Anasetti C, Bejanyan N, Elmariah H. Comparison of Outcomes of Haploidentical Peripheral Blood Stem Cell Transplantation with Post-Transplant Cyclophosphamide in Older Versus Younger Patients. Cancers (Basel). 2025 Jan.17(2). Pubmedid: 39858092. Pmcid: PMC11763395.
• Sweiss K, Wagner C, Anto E, Greene T, Sun R, Gonzalez R, Puglianini OC, Freeman C, Ionescu F, Patel K, Ferreri C, Gaballa M, Shune L, McGuirk J, Sidana S, Hovanky V, Khouri J, Raza S, Anwer F, Dima D, Hashmi H, Davis J, Afrough A, Kaur G, Anderson JL, Forsberg P, Herr M, Hansen DK, Hakan Kocoglu M, Sborov D. Fludarabine Lymphodepletion Exposure is Associated with Toxicities after Idecabtagene-Vicleucel in Relapsed/Refractory Multiple Myeloma: Real-World Experience from the US Myeloma Immunotherapy Consortium. Transplant Cell Ther. 2025 Dec.31(12):989-999. Pubmedid: 40972962.
• Galarza Fortuna GM, Peres LC, Nazarenko E, De Menezes Silva Corraes A, Hovanky V, Shune L, McGuirk JP, de Avila G, Khouri J, Dima D, Gaballa MR, Dhakal B, Forsberg PA, Godara A, Afrough A, Anderson LD, Herr MM, Davis JA, Mann H, Purvey S, Clark WB, Htut MM, Beitinjaneh AM, Pereira DL, Kocoglu M, Ferreri CJ, Atrash S, Voorhees PM, Rossi AC, Richard S, Hashmi H, Patel KK, Sidana S, Lin Y, Hansen DK, Sborov DW. Safety and efficacy of BCMA-directed chimeric antigen receptor T-cell therapy for the treatment of plasma cell leukemia. Blood Adv. 2025 Dec.9(23):6009-6018. Pubmedid: 40875887. Pmcid: PMC12686786.
• Freeman CL, Abraham-Miranda J, Menges M, Atkins RM, Noble J, Liu H, Corallo S, Cuadrado Delgado LA, Ribickas AJ, Savid-Frontera C, de Avila G, Castaneda Puglianini OA, Ochoa-Bayona J, Hansen DK, Alsina M, Baz R, Nishihori T, Shain KH, Locke FL. Enhanced CAR-T cell function and mitochondrial fitness from earlier unfractionated stem cell product in multiple myeloma. Mol Ther. 2025 Aug.33(8):3576-3589. Pubmedid: 40253586. Pmcid: PMC12461620.
• Razzo BM, Midha S, Portuguese AJ, Grajales-Cruz AF, De Menezes Silva Corraes A, Costello P, Liu Y, Sperling AS, Nadeem O, Dima D, Banerjee R, Cowan AJ, Afrough A, Anderson LD, Lieberman-Cribbin A, Kaur G, Goyal A, Atrash S, Ferreri CJ, Voorhees PM, Pasvolsky O, Lee HC, Patel KK, Julian KL, Forsberg PA, Herr MM, Chhabra S, Parrondo RD, Lin Y, Chen A, Susanibar-Adaniya SP, Khouri J, Raza S, Anwer F, Vazquez-Martinez M, Castaneda Puglianini O, Sborov DW, Davis JA, Rossi A, Shune L, Bhurtel J, Hwang WT, Hansen DK, Sidana S, Garfall AL, Richard S. Real-World Experience with Teclistamab for Relapsed/Refractory Multiple Myeloma from the US Myeloma Immunotherapy Consortium. Blood Cancer Discov. 2025 Aug.OF1-OF11. Pubmedid: 40778675.
• Ailawadhi S, Anderson LD, Dhakal B, Shune L, Sborov DW, Hansen DK. Optimizing Selection of Bridging Therapies Prior to CAR-T Therapy Administration for Multiple Myeloma: Clinical Pearls From an Expert Roundtable. Clin Lymphoma Myeloma Leuk. 2025 Aug. Pubmedid: 40885679.
• Golmohammadi M, Raza S, Albayyadhi M, Sholehrasa H, Khouri J, Williams L, Hansen DK, Moradi A, Xu X, Albliwi M, Ali AH, Dima D, Anwer F, Paul B, Jaberi-Douraki M. Comprehensive assessment of adverse event profiles associated with bispecific antibodies in multiple myeloma. Blood Cancer J. 2025 Aug.15(1):130. Pubmedid: 40750760. Pmcid: PMC12316967.
• Palfi S, Peres LC, Koelmeyer H, Alsina M, Baz RC, Blue BJ, Corallo S, De Avila G, Freeman C, Gonzalez R, Grajales-Cruz A, Harvey K, Liu HD, Nishihori T, Oliveira GH, Oswald LB, Castaneda Puglianini O, Selvakumar S, Sharma AB, Wang E, Shain KH, Jain M, Locke FL, Alomar M, Hansen DK, Lee DH. Cardiovascular adverse events and outcomes after anti-BCMA CAR-T for relapsed and refractory multiple myeloma. Blood Cancer J. 2025 Apr.15(1):63. Pubmedid: 40229239. Pmcid: PMC11997198.
• Akhtar OS, Oloyede T, Brazauskas R, Afrough A, Hashmi H, Sidana S, Ahmed N, Bye M, Hansen DK, Ferreri CJ, Dhakal B, Dhanda DS, Harrison MJ, Kitali A, Landau HJ, Mirza AS, Patel J, Patwardhan P, Qazilbash MH, Patel KK, Nishihori T, Ganguly S, Gowda L, Anderson LD, Pasquini MC, Usmani SZ, Freeman CL. Outcomes of older adults and frail patients receiving idecabtagene vicleucel: a CIBMTR study. Blood Adv. 2025 Apr.9(7):1587-1592. Pubmedid: 39786391. Pmcid: PMC11986210.
• Freeman CL, Noble J, Menges M, Villanueva R, Nakashima JY, Figura NB, Tonseth RP, Idiaquez DW, Skelson L, Smith EC, Abraham-Miranda J, Corallo S, De Avila G, Castaneda Puglianini O, Liu HD, Alsina M, Nishihori T, Shain KH, Baz RC, Blue BJ, Grajales-Cruz A, Koomen JM, Atkins RM, Hansen DK, Siqueira Silva A, Kim J, Balagurunathan Y, Locke FL. Tumor burden quantified by soluble B-cell maturation antigen and metabolic tumor volume determines myeloma CAR-T outcomes. Blood. 2025 Apr.145(15):1645-1657. Pubmedid: 39652773.
• Kalariya N, Hildebrandt MAT, Hansen DK, Sidana S, Khouri J, Ferreri CJ, Doyle WN, Castaneda Puglianini OA, Freeman CL, Hovanky V, Hosoya H, Shune L, Patel KK. Clinical outcomes after idecabtagene vicleucel in older patients with multiple myeloma: a multicenter real-world experience. Blood Adv. 2024 Sep.8(17):4679-4688. Pubmedid: 39042903. Pmcid: PMC11402173.
• Handley G, Yepes A, Eliassen E, Dominguez G, Pasikhova Y, Klinkova O, Baluch A, Febres-Aldana AJ, Alsina M, Elmariah H, Khimani F, Hansen DK, Freeman CL, Jain MD, Locke F, Lazaryan A, Liu HD, Mishra A, Mirza AS, Nishihori T, Ochoa L, Perez L, Pidala J, Puglianini OC, Nieder M, Perna F, Kim J, Bejanyan N, Faramand R. Outcomes of Haploidentical Stem Cell Transplant Recipients With HHV-6B Reactivation. Open Forum Infect Dis. 2024 Oct.11(10):ofae564. Pubmedid: 39411216. Pmcid: PMC11475747.
• Fortuna GG, Banerjee R, Savid-Frontera C, Song J, Morán-Segura CM, Nguyen JV, Lekakis L, Fernandez-Pol S, Samraj AN, Naresh KN, Vazquez-Martinez M, Baz RC, Spiegel JY, Mikkilineni L, Gubatan JM, Sidana S, de Menezes Silva Corraes A, Kalariya NM, Patel KK, Shim KG, Fonseca R, Ferreri C, Voorhees PM, Richard S, Valdes CR, Sireesha Asoori, Wolf JL, Cowan AJ, Sborov DW, Locke FL, Lin Y, Wang Y, Hansen DK. Immune effector cell-associated enterocolitis following chimeric antigen receptor T-cell therapy in multiple myeloma. Blood Cancer J. 2024 Oct.14(1):180. Pubmedid: 39414769. Pmcid: PMC11484697.
• Hansen DK, Gautam S, Lafeuille MH, Rossi C, Moore B, Tardif-Samson A, Thompson-Leduc P, Fu AZ, Cortoos A, Kaila S, Fonseca R. Comparison of Time to Next Treatment or Death Between Front-Line Daratumumab, Lenalidomide, and Dexamethasone (DRd) Versus Bortezomib, Lenalidomide, and Dexamethasone (VRd) Among Transplant-Ineligible Patients With Multiple Myeloma. Cancer Med. 2024 Nov.13(21):e70308. Pubmedid: 39486091. Pmcid: PMC11530241.
• Hashmi H, Hansen DK, Peres LC, Puglianini OC, Freeman C, De Avila G, Sidana S, Shune L, Sborov DW, Davis J, Wagner C, Kocoglu MH, Atrash S, Voorhees P, Simmons G, Ferreri C, Kalariya N, Anderson LD, Afrough A, Dima D, Khouri J, McGuirk J, Locke F, Baz R, Patel KK, Alsina M. Factors associated with refractoriness or early progression after idecabtagene vicleucel in patients with relapsed/ refractory multiple myeloma: US Myeloma Immunotherapy Consortium real world experience. Haematologica. 2024 May.109(5):1514-1524. Pubmedid: 37855036. Pmcid: PMC11063864.
• Akhtar OS, Modi K, Kim J, Skellson L, Smith E, Al-Jumayli MA, Extermann M, De Avila G, Parker N, Castaneda-Puglianini O, Grajales-Cruz A, Baz R, Blue B, Shain K, Alsina M, Liu H, Nishihori T, Jain MD, Locke FL, Hansen DK, Freeman CL. Simple Score of Albumin and CRP Predicts High-Grade Toxicity in Patients with Multiple Myeloma Receiving CAR-T Therapy. Transplant Cell Ther. 2024 Mar.30(3):283.e1-283.e10. Pubmedid: 38123069.
• Sidana S, Peres LC, Hashmi H, Hosoya H, Ferreri C, Khouri J, Dima D, Atrash S, Voorhees P, Simmons G, Sborov DW, Kalariya N, Hovanky V, Bharadwaj S, Miklos D, Wagner C, Kocoglu MH, Kaur G, Davis JA, Midha S, Janakiram M, Freeman C, Alsina M, Locke F, Gonzalez R, Lin Y, McGuirk J, Afrough A, Shune L, Patel KK, Hansen DK. Idecabtagene vicleucel chimeric antigen receptor T-cell therapy for relapsed/refractory multiple myeloma with renal impairment. Haematologica. 2024 Mar.109(3):777-786. Pubmedid: 37731379. Pmcid: PMC10905101.
• Akhtar OS, Sheeba BA, Azad F, Alessi L, Hansen D, Alsina M, Baz R, Shain K, Grajales Cruz A, Castaneda Puglianini O, Liu H, Blue B, Nishihori T, Al Jumayli M, Extermann M, Locke FL, Mhaskar R, Freeman CL. Safety and efficacy of anti-BCMA CAR-T cell therapy in older adults with multiple myeloma: A systematic review and meta-analysis. Geriatr Oncol. 2024 Mar.15(2):101628. Pubmedid: 37723045.
• Hansen DK, Dhakal B, Hamadani M, Dingli D, Jain T, Huff CA, Janakiram M, Liu YH, De Braganca KC, Lodowski N, Sander J, Okorozo P, McFarland L, Perciavalle M, Huo S, Qureshi ZP, Patel KK. Clinician and administrator perspectives on outpatient administration of ciltacabtagene autoleucel in relapsed or refractory multiple myeloma. Front Immunol. 2024 Jun.15:1405452. Pubmedid: 38915401. Pmcid: PMC11194690.
• Zanwar S, Sidana S, Shune L, Puglianini OC, Pasvolsky O, Gonzalez R, Dima D, Afrough A, Kaur G, Davis JA, Herr M, Hashmi H, Forsberg P, Sborov D, Anderson LD, McGuirk JP, Wagner C, Lieberman-Cribbin A, Rossi A, Freeman CL, Locke FL, Richard S, Khouri J, Lin Y, Patel KK, Kumar SK, Hansen DK. Impact of extramedullary multiple myeloma on outcomes with idecabtagene vicleucel. J Hematol Oncol. 2024 Jun.17(1):42. Pubmedid: 38845015. Pmcid: PMC11157748.
• Peres LC, Oswald LB, Dillard CM, De Avila G, Nishihori T, Blue BJ, Freeman CL, Locke FL, Alsina M, Castaneda Puglianini OA, Shune L, Sborov DW, Wagner C, Dima D, Hashmi H, Davis JA, Kocoglu MH, Badros AZ, Atrash S, Simmons G, Kalariya N, Ferreri CJ, Anderson LD, Afrough A, Kaur G, Lin Y, Liu L, Nadeem O, Voorhees PM, Khouri J, McGuirk JP, Sidana S, Hansen DK, Patel KK. Racial and ethnic differences in clinical outcomes among patients with multiple myeloma treated with CAR T-cell therapy. Blood Adv. 2024 Jan.8(1):251-259. Pubmedid: 37855718.
• Khouri J, Dima D, Li H, Hansen D, Sidana S, Shune L, Anwer F, Sborov D, Wagner C, Kocoglu MH, Atrash S, Voorhees P, Peres L, Hovanky V, Simmons G, Williams L, Raza S, Afrough A, Anderson L, Fererri C, Hashmi H, Davis J, McGuirk J, Goldsmith S, Borogovac A, Lin Y, Midha S, Nadeem O, Locke FL, Baz R, Hamilton B, Alsina M, Sauter C, Patel K, Kaur G. Absolute Lymphocyte Count and Outcomes of Multiple Myeloma Patients Treated with Idecabtagene Vicleucel: The US Myeloma Immunotherapy Consortium Real- World Experience. Transplant Cell Ther. 2024 Aug.30(8):790.e1-790.e16. Pubmedid: 38834151.
• Hansen DK, Lu X, Puglianini OC, Sorensen S, Usmani SZ, Zhang E, Huo S, Zhang Y, Qureshi ZP, Jagannath S. Cost-per-responder analysis of patients with lenalidomide-refractory multiple myeloma receiving ciltacabtagene autoleucel in CARTITUDE-4. Front Immunol. 2024 Aug.15:1408892. Pubmedid: 39234256. Pmcid: PMC11372240.
• Afrough A, Hashmi H, Hansen DK, Sidana S, Ahn C, Peres LC, Dima D, Freeman CL, Puglianini OC, Kocoglu MH, Atrash S, Voorhees PM, Shune L, McGuirk JP, Simmons G, Sborov DW, Davis JA, Kaur G, Sannareddy A, Ferreri CJ, Gaballa MR, Goldsmith S, Nadeem O, Midha S, Wagner CB, Locke FL, Patel KK, Khouri J, Anderson LD, Lin Y. Real-world impact of bridging therapy on outcomes of ide-cel for myeloma in the U.S. Myeloma Immunotherapy Consortium. Blood Cancer J. 2024 Apr.14(1):63. Pubmedid: 38609386. Pmcid: PMC11015040.
• Rejeski K, Wang Y, Hansen DK, Iacoboni G, Bachy E, Bansal R, Penack O, Müller F, Bethge WA, Munoz J, Mohty R, Bücklein VL, Barba P, Locke FL, Lin Y, Jain MD, Subklewe M. Applying the EHA/EBMT grading for ICAHT after CAR-T: comparative incidence and association with infections and mortality. Blood Adv. 2024 Apr.8(8):1857-1868. Pubmedid: 38181508. Pmcid: PMC11007437.
• Oswald LB, Gudenkauf LM, Li X, De Avila G, Peres LC, Kirtane K, Gonzalez BD, Hoogland AI, Nguyen O, Rodriguez Y, Baz RC, Shain KH, Alsina M, Locke FL, Freeman C, Castaneda Puglianini O, Nishihori T, Liu H, Blue B, Grajales-Cruz A, Jim HSL, Hansen DK. Patient-Reported Outcomes among Multiple Myeloma Patients Treated with Standard of Care Idecabtagene Vicleucel. Cancers (Basel). 2023 Sep.15(19). Pubmedid: 37835405. Pmcid: PMC10571575.
• Hansen DK, Bixby T, Fixler K, Shea L, Brittle C, Brunisholz K, Liu YH, Huo JS. Experience of Autologous Stem Cell Transplant in Multiple Myeloma: The Patient and Caregiver Perspective. J Patient Exp. 2023 Sep.10. Pubmedid: 37766811. Pmcid: PMC10521273.
• Emanuel NA, Price S, Hansen DK, Whiting J, Kim J, Gaskill E. Impact of weight and creatinine adjustments on the accuracy of Cockcroft-gault equation in hematopoietic cell transplant patients. Clin Transplant. 2023 Oct.37(10):e15059. Pubmedid: 37395991.
• Rejeski K, Hansen DK, Bansal R, Sesques P, Ailawadhi S, Logue JM, Bräunlein E, Cordas Dos Santos DM, Freeman CL, Alsina M, Theurich S, Wang Y, Krackhardt AM, Locke FL, Bachy E, Jain MD, Lin Y, Subklewe M. The CAR-HEMATOTOX score as a prognostic model of toxicity and response in patients receiving BCMA-directed CAR-T for relapsed/refractory multiple myeloma. J Hematol Oncol. 2023 Jul.16(1):88. Pubmedid: 37525244. Pmcid: PMC10391746.
• Hansen DK, Sidana S, Peres LC, Patel KK. Reply to R. Chakraborty et al. J Clin Oncol. 2023 Jul.41(20):3658-3659. Pubmedid: 37235841. Pmcid: PMC10325766.
• Hansen DK, Liu YH, Ranjan S, Bhandari H, Potluri R, McFarland L, De Braganca KC, Huo S. The Impact of Outpatient versus Inpatient Administration of CAR-T Therapies on Clinical, Economic, and Humanistic Outcomes in Patients with Hematological Cancer: A Systematic Literature Review. Cancers (Basel). 2023 Dec.15(24). Pubmedid: 38136292. Pmcid: PMC10741664.
• Ferreri CJ, Hildebrandt MAT, Hashmi H, Shune LO, McGuirk JP, Sborov DW, Wagner CB, Kocoglu MH, Rapoport A, Atrash S, Voorhees PM, Khouri J, Dima D, Afrough A, Kaur G, Anderson LD, Simmons G, Davis JA, Kalariya N, Peres LC, Lin Y, Janakiram M, Nadeem O, Alsina M, Locke FL, Sidana S, Hansen DK, Patel KK, Castaneda Puglianini OA. Real-world experience of patients with multiple myeloma receiving ide-cel after a prior BCMA-targeted therapy. Blood Cancer J. 2023 Aug.13(1):117. Pubmedid: 37558706. Pmcid: PMC10412575.
• Lee DH, Kumar A, Mohammed T, Peres LC, Alsina M, Bachmeier CA, Blue B, Brayer J, Chandrasekhar S, Grajales-Cruz AF, De Avila G, Elmariah H, Faramand RG, Freeman CL, Jain MD, Khadka S, Khimani F, Liu H, Nishihori T, Oswald LB, Castaneda Puglianini OA, Shain KH, Smith E, Baz RC, Locke FL, Oliveira GH, Alomar M, Hansen DK. Cardiac events after standard of care idecabtagene vicleucel for relapsed and refractory multiple myeloma. Blood Adv. 2023 Aug.7(16):4247-4257. Pubmedid: 37307173. Pmcid: PMC10424134.
• Hansen DK, Sidana S, Peres LC, Colin Leitzinger C, Shune L, Shrewsbury A, Gonzalez R, Sborov DW, Wagner C, Dima D, Hashmi H, Kocoglu MH, Atrash S, Simmons G, Kalariya N, Ferreri C, Afrough A, Kansagra A, Voorhees P, Baz R, Khouri J, Alsina M, McGuirk J, Locke FL, Patel KK. Idecabtagene Vicleucel for Relapsed/Refractory Multiple Myeloma: Real-World Experience From the Myeloma CAR T Consortium. J Clin Oncol. 2023 Apr.41(11):2087-2097. Pubmedid: 36623248. Pmcid: PMC10082273.
• Oswald LB, Li X, Carvajal R, Hoogland AI, Gudenkauf LM, Hansen DK, Alsina M, Locke FL, Rodriguez Y, Irizarry-Arroyo N, Robinson EJ, Jim HSL, Gonzalez BD, Kirtane K. Longitudinal Collection of Patient-Reported Outcomes and Activity Data during CAR-T Therapy: Feasibility, Acceptability, and Data Visualization. Cancers (Basel). 2022 May.14(11). Pubmedid: 35681722. Pmcid: PMC9179384.
• Kansagra A, Dispenzieri A, Fraser R, Estrada-Merly N, Sidana S, Nishihori T, Hansen DK, Anderson LD, Banerjee R, Bumma N, Dhakal B, Khouri J, Landau H, Lee CH, Mian H, Nathan S, Savani BN, Kumar SK, Qazilbash MH, Shah N, D'Souza A. Outcomes after autologous hematopoietic cell transplantation in POEMS syndrome and comparison with multiple myeloma. Blood Adv. 2022 Jul.6(13):3991-3995. Pubmedid: 35507742. Pmcid: PMC9278304.
• Peres LC, Hansen DK, Maura F, Kazandjian D. The knowns and unknowns of disparities, biology, and clinical outcomes in Hispanic and Latinx multiple myeloma patients in the U.S. Semin Oncol. 2022 Feb.49(1):3-10. Pubmedid: 35219512.
• Logue JM, Peres LC, Hashmi H, Colin-Leitzinger C, Shrewsbury AM, Hosoya H, Gonzalez R, Copponex C, Kottra KH, Hovanky V, Sahaf B, Patil S, Lazaryan A, Jain MD, Baluch A, Klinkova O, Bejanyan N, Faramand RG, Elmariah H, Khimani F, Davila ML, Mishra A, Blue B, Grajales-Cruz AF, Castaneda Puglianini O, Liu H, Nishihori T, Freeman CL, Brayer J, Shain KH, Baz R, Locke FL, Alsina M, Sidana S, Hansen DK. Early cytopenias and infections after standard of care idecabtagene vicleucel in relapsed or refractory multiple myeloma. Blood Adv. 2022 Dec.6(24):6109-6119. Pubmedid: 35939783. Pmcid: PMC9768247.
• Masood A, Iqbal Q, Ehsan H, Davis JA, Hansen DK, Hashmi H. Efficacy and safety of selinexor-based regimens for relapsed/refractory multiple myeloma: a systematic review of literature. Ann Hematol. 2022 Dec.101(12):2601-2610. Pubmedid: 36214853.
• Zhang Y, Duncanson L, Brayer J, Reu F, Hansen D, Alsina M, Nishihori T, Ochoa-Bayona J, Liu H, Shain K, Thompson Z, Baz R, Blue B. Adding Cyclophosphamide to Bortezomib and Dexamethasone was not Associated With Improved Outcomes of Patients With Newly Diagnosed Light Chain Amyloidosis: A Retrospective Study. Clin Lymphoma Myeloma Leuk. 2022 Aug.22(8):e770-e776. Pubmedid: 35504808.
• Hansen DK, Dam M, Faramand RG. Toxicities associated with adoptive cellular therapies. Best Pract Res Clin Haematol. 2021 Sep.34(3):101287. Pubmedid: 34625233.
• Khimani F, Ranspach P, Elmariah H, Kim J, Whiting J, Nishihori T, Locke FL, Perez Perez A, Dean E, Mishra A, Perez L, Lazaryan A, Jain MD, Nieder M, Liu H, Faramand R, Hansen D, Alsina M, Ochoa L, Davila M, Anasetti C, Pidala J, Bejanyan N. Increased Infections and Delayed CD4+ T Cell but Faster B Cell Immune Reconstitution after Post-Transplantation Cyclophosphamide Compared to Conventional GVHD Prophylaxis in Allogeneic Transplantation. Transplant Cell Ther. 2021 Nov.27(11):940-948. Pubmedid: 34329754.
• Hansen DK, Kim J, Thompson Z, Hussaini M, Nishihori T, Ahmad A, Elmariah H, Faramand R, Mishra A, Davila ML, Khimani F, Lazaryan A, Sallman D, Liu H, Perez LE, Fernandez H, Nieder ML, Lancet JE, Pidala JA, Anasetti C, Bejanyan N. ELN 2017 Genetic Risk Stratification Predicts Survival of Acute Myeloid Leukemia Patients Receiving Allogeneic Hematopoietic Stem Cell Transplantation. Transplant Cell Ther. 2021 Mar.27(3):256.e1-256.e7. Pubmedid: 33781526. Pmcid: PMC8711732.
• Khimani F, Dutta M, Faramand R, Nishihori T, Perez AP, Dean E, Nieder M, Perez L, Mishra A, Elmariah H, Davila M, Ochoa L, Alsina M, Lazaryan A, Bejanyan N, Hansen D, Jain M, Locke F, Liu H, Pidala J, Shah B, Mhaskar R. Impact of Total Body Irradiation-Based Myeloablative Conditioning Regimens in Patients with Acute Lymphoblastic Leukemia Undergoing Allogeneic Hematopoietic Stem Cell Transplantation: Systematic Review and Meta-Analysis. Transplant Cell Ther. 2021 Jul.27(7):620.e1-620.e9. Pubmedid: 33798768.

• Title: Real-World Patient Characteristics, Utilization, and Outcomes of Teclistamab at Moffitt Cancer Center – A Multiphase Chart Review Study
  Award Number: 24-0166, Amendment 1
  Sponsor: JANSSEN RESEARCH & DEVELOPMENT
  Grajales-Cruz, A. (PD/PI), Hansen, D. (Co-PD/PI)
• Title: PILOT STUDY TO DEVELOP A PREDICTIVE MODEL OF IMMUNE-RELATED ADVERSE EVENTS IN MYELOMA PATIENTS TREATED WITH IDECABTAGENE VICLEUCEL IN THE STANDARD OF CARE SETTING
  Award Number: 22VA024 SOW1
  Sponsor: Bristol Myers Squibb (BMS)
  Hansen, D. (PD/PI), Peres, L. (Co-PD/PI)
• Title: Exploratory Analysis of Real-world Patient Profiles that Correlate with Manufacturing and Clinical Endpoints in Late-line Relapsed Refractory Multiple Myeloma Patients Treated with idecabtagene vicleucel
  Award Number: 22VA024 SOW2, First Amendment
  Sponsor: Bristol Myers Squibb (BMS)
  Hansen, D. (PD/PI)
• Title: SOW #7: Real-World Outcomes of Adult Patients with Triple-Class Exposed Relapsed or Refractory Multiple Myeloma: Evidence from a Multicenter Retrospective Study (MMIRROR-1)
  Award Number: 18VA031-S9
  Sponsor: Kite Pharma
  Hansen, D. (PD/PI)
• Title: Characterizing and Evaluating Bridging Therapy and Disparities Among Relapsed/Refractory Multiple Myeloma Patients Treated with Idecabtagene Vicleucel in a Real-World Setting
  Award Number: 22VA024-S6
  Sponsor: Bristol Myers Squibb (BMS)
  Hansen, D. (PD/PI), Peres, L. (Co-PD/PI)
• Title: Effectiveness of chimeric antigen receptor T (CAR-T) cells therapy after previous failure with BCMA-based treatment in patients with relapsed or refractory multiple myeloma
  Award Number: 22VA080-S2, 24-0167
  Sponsor: JANSSEN RESEARCH & DEVELOPMENT
  Hansen, D. (PD/PI), Peres, L. (PD/PI)
• Title: Real-world Clinical and Patient-reported Outcomes among Patients with Relapsed/refractory Multiple Myeloma Treated with Commercial CAR-T Therapy
  Award Number:
  Sponsor: Foundation Support-Rsch
  Hansen, D. (PD/PI), Oswald, L. (PD/PI), Peres, L. (PD/PI)
• Title: Survivorship in Patients with Multiple Myeloma Treated with Chimeric Antigen Receptor T-Cell Therapy
  Award Number: 5R01CA281756-02
  Sponsor: National Cancer Institute (NCI)
  Hansen, D. (PD/PI), Oswald, L. (PD/PI), Peres, L. (PD/PI)